The university hospital of Heidelberg is one of the largest medical centers in the Federal Republic of Germany behind the Charité in Berlin and the LMU Klinikum in Munich.

There are 1,900 (2012) beds in Universitatsklinikum Heidelberg.

During the past decade, Universitatsklinikum Heidelberg conducted 269 clinical trials. In the 10-year time frame, 269 clinical trials started and 111 clinical trials were completed, i.e. on average, 41.3% percent of trials that started reached the finish line to date. In the past 5 years, 112 clinical trials started and 69 clinical trials were completed. i.e. 61.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitatsklinikum Heidelberg" #1 sponsor was "Hoffmann-La Roche" with 23 trials, followed by "Boehringer Ingelheim" with 21 trials sponsored, "Janssen Research & Development, LLC" with 18 trials sponsored, "Celgene" with 15 trials sponsored and "Bayer" with 15 trials sponsored. Other sponsors include 338 different institutions and companies that sponsored additional 195 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitatsklinikum Heidelberg" #1 collaborator was "Merck Sharp & Dohme LLC" with 10 trials as a collaborator, "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 8 trials as a collaborator, "Eli Lilly and Company" with 5 trials as a collaborator, "Hoffmann-La Roche" with 5 trials as a collaborator and "Bristol-Myers Squibb" with 4 trials as a collaborator. Other collaborators include 250 different institutions and companies that were collaborators in the rest 208 trials.

According to Clinical.Site data, the most researched conditions in "Universitatsklinikum Heidelberg" are "Multiple Myeloma" (25 trials), "Coronary Artery Disease" (11 trials), "Acute Myeloid Leukemia" (10 trials), "Heart Failure" (10 trials) and "Leukemia" (9 trials). Many other conditions were trialed in "Universitatsklinikum Heidelberg" in a lesser frequency.

Most popular intervention types in "Universitatsklinikum Heidelberg" are "Drug" (312 trials), "Device" (61 trials), "Other" (37 trials), "Biological" (36 trials) and "Procedure" (27 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (71 trials), "Dexamethasone" (18 trials), "Rituximab" (12 trials), "Daratumumab" (11 trials) and "Bortezomib" (10 trials). Other intervention names were less common.

The vast majority of trials in "Universitatsklinikum Heidelberg" are 415 trials for "All" genders, 11 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are 144 active trials in "Universitatsklinikum Heidelberg". 2 are not yet recruiting, 81 are recruiting, 58 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 236 completed trials in Universitatsklinikum Heidelberg, 1 suspended trials, and 36 terminated clinical trials to date.

Out of the total trials that were conducted in Universitatsklinikum Heidelberg, 51 "Phase 1" clinical trials were conducted, 131 "Phase 2" clinical trials and 155 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 40 trials that are defined as “Not Applicable".